-
Survivors of childhood bone cancer are at risk for learning, memory problems
12/23/2015
Research from the St. Jude LIFE study found childhood osteosarcoma survivors have a higher risk for learning and memory problems.
-
Clues to how aggressive sarcomas beat chemotherapy drugs
12/18/2015
Enzyme linked to neurodegenerative disorders may play a reversible role in enhancing the aggressiveness of sarcoma tumors.
-
Another step in the long road to hearing restoration
12/01/2015
Drug discovery project raises hopes for drugs targeting intrinsically disordered proteins, which are associated with range of human diseases.
-
Surprising number of young cancer patients are predisposed to the disease
11/18/2015
Landmark study shows almost one in 10 children with cancer were born with an increased genetic risk for the disease.
-
Gene variations offer clues to cancer risk
10/27/2015
Evidence suggests that variations in the ETV6 gene may play a significant role in inherited predisposition to most common childhood cancer — ALL.
-
Computer games aid attention and memory in cancer survivors
10/12/2015
Online cognitive training offers expanded access to effective method of improving working memory and easing late effects of cancer treatment.
-
Discovery may help ease lung disorder in at-risk newborns
09/29/2015
St. Jude researchers discovered that bile acid buildup in the liver during pregnancy can cause intrahepatic cholestasis of pregnancy.
-
Salad dressing offers window into how cells organize and function
09/24/2015
Researchers identify mechanism that plays key role in cellular organization and offers insight into treatment of degenerative diseases like ALS.
-
Two leukemias. One shared genetic alteration. Why are the outcomes so different?
08/27/2015
Researchers reveal how alterations in IKZF1 gene drive an aggressive leukemia and a strategy to enhance the effectiveness of existing therapies
-
Scientists uncover how a common mutation causes brain diseases
08/26/2015
St. Jude scientists lead effort that uncovers the mechanism involved in the most common genetic cause of two neurodegenerative disorders.
-
Discovery yields promising strategy for making tumor cells easier to kill
07/30/2015
St. Jude scientists have discovered another way the tumor suppressor protein p53 earns its title as guardian of the genome.
-
Targeted therapy stalls or shrinks tumors in some medulloblastoma patients
07/29/2015
A new era of personalized medicine has begun for some patients with the brain tumor medulloblastoma.
-
Improving diagnosis of chest tumors
07/22/2015
St. Jude researchers have discovered a potential new method for determining whether masses in the chest cavity are a fungal infection or a tumor without performing a biopsy.
-
Teaching old cells new tricks
07/02/2015
St. Jude scientists use new methods to show that one type of stem cell is superior to another for treating retinal degeneration in research that could significantly advance such treatments
-
18 genes identified that contribute to childhood brain tumor ependymoma
06/15/2015
St. Jude discovery lays the foundation for developing new, much needed chemotherapy agents and finds evidence that anti-cholesterol drugs called statins slow growth of ependymoma tumor cells.
-
Changes in treatment extend the lifespan of long-term survivors of childhood cancer
05/31/2015
Research led by St. Jude found that deaths from late effects of childhood cancer treatment have declined in recent decades and survivors are living longer.
-
Dr. Paul Taylor named Howard Hughes Medical Institute investigator
05/19/2015
J. Paul Taylor, M.D., Ph.D., of St. Jude Children's Research Hospital, has been recognized as one of the nation's leading biomedical researchers by the Howard Hughes Medical Institute.
-
Preserving the power of glucocorticoids to fight leukemia
05/04/2015
Researchers led by St. Jude scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases.
-
A better tool for mining the cancer genome
05/04/2015
St. Jude scientists have developed a significantly better computer tool for finding genetic alterations that play an important role in many cancers but were difficult to identify with whole-genome sequencing.
-
Finding a “brake” for inflammation
04/21/2015
Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis, colitis and other autoimmune disorders.
-
Measuring response to leukemia treatment may save more lives
03/19/2015
Measuring treatment response proves to be a powerful tool for guiding leukemia therapy.
-
Genome reveals clues for better diagnosis and treatment of rare adrenal cancer
03/06/2015
St. Jude scientists identify key molecular events in pediatric adrenocortical tumors. The findings could help clinicians identify most malignant subtypes and lead to better treatment.
-
Aggressive infant leukemia has surprisingly few genetic changes
03/06/2015
Researchers with the Pediatric Cancer Genome Project have completed the most comprehensive DNA analysis yet of the most common form of ALL in infants.
-
Evidence grows that sun protection must start early and be a lifelong habit
03/04/2015
The Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy.
-
Discovery may help reduce cancer drug’s side effects
02/24/2015
Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug.
-
Basic question yields possible strategy for combating major tropical disease
02/18/2015
Researchers like to ask basic questions about how the world and the things in it work. Answers to those questions can advance science and protect health.
-
Yearly pituitary screening helps childhood cancer survivors manage risk
02/13/2015
St. Jude researchers have reported more evidence that many childhood cancer survivors need their pituitary function checked annually.
-
Digging deeper to save lives and hearing
02/09/2015
Cisplatin is one of the most widely used anti-cancer drugs. Many patients treated with the drug also have serious side effects like hearing loss.
-
Drug side effects explained in patients of East Asian ancestry
01/26/2015
St. Jude scientists have linked inherited variations in a second gene to reduced tolerance of a key cancer drug. Findings will aid efforts to improve chemotherapy safety and effectiveness.
-
Tumor suppressor protein helps immune system stay balanced
01/15/2015
Scientists at St. Jude have discovered that a protein widely known for preventing tumors also helps regulatory T cells do their job.
